Alnylam Pharmaceuticals, Inc. (ALNY) fundamentals score
Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, its or it) is a global commercial-stage biopharmaceutical company developing novel therapeutics based on ribonucleic acid interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 7.4 out of 10, Good long-term fundamentals
- Growth: 7.9/10
- Profitability: 8.4/10
- Financial health: 8.0/10
- Earnings quality: 6.7/10
- Valuation: 5.1/10
Scores are calculated from Alnylam Pharmaceuticals, Inc.’s SEC filings, using the 12 months through 2025-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10